FDA Accepts Arcutis Application for Roflumilast Cream 015 as Treatment for Atopic Dermatitis
On December 2, 2023, a significant development took place in the field of dermatology as the U.S. Food and Drug ...
Tag: ARQT
Significant Adjustment in Price Target for Arcutis Biotherapeutics Sparks Investor Caution
On November 13, 2023, Morgan Stanley analyst Nigel Dally made a significant adjustment to the price target for Arcutis Biotherapeutics ...
Arcutis Biotherapeutics Receives Analyst Ratings and Price Target
Arcutis Biotherapeutics (NASDAQ: ARQT) has recently received ratings from eight analysts. These ratings are as follows: - Bullish: 4 - ...
Analyst Maintains Buy Rating on Arcutis Biotherapeutics with Lowered Price Target
On November 6, 2023, Serge Belanger, an analyst at Needham, expressed his positive outlook on Arcutis Biotherapeutics (NASDAQ:ARQT) by maintaining ...
Anticipating Arcutis Biotherapeutics Quarterly Earnings and Stock Performance
Arcutis Biotherapeutics (NASDAQ:ARQT) is set to announce its latest quarterly earnings on November 3, 2023. Analysts predict that the company ...
WisdomTree Reports Impressive Q3 Earnings with Significant Growth
On October 27, 2023, WisdomTree (NYSE:WT) released its earnings report for the third quarter of the year, showcasing impressive results. ...
WEX Inc Announces Q3 2023 Financial Results and Plans to Acquire Payzer
WEX Inc. (WEX) has recently released its third-quarter 2023 financial results and provided guidance for the fourth quarter and full ...
Arcutis Biotherapeutics Recent Public Offering and Potential Growth Opportunities
Arcutis Biotherapeutics made a significant announcement on October 20, 2023, regarding the pricing of their latest public offering. They revealed ...
ZORYVE Cream 03 Effective and WellTolerated Treatment for Plaque Psoriasis
October 20, 2023 New findings reveal that the usage of ZORYVE cream 0.3% resulted in significant improvement of plaque psoriasis ...
Arcutis Biotherapeutics Announces Ambitious Plan for Underwritten Public Offering
On October 19, 2023, Arcutis Biotherapeutics, a pioneering biopharmaceutical company, unveiled its ambitious plan for a proposed underwritten public offering. ...